Home › Funds › Vanguard › Vanguard Health Care Fund
Fund family: Vanguard · Filed by VANGUARD SPECIALIZED FUNDS (CIK 734383) · SEC series S000002922
Share classes and tickers: VGHAX (C000008008), VGHCX (C000008007)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 879 with, 15 against, 6 abstentions (not counted as with management); 29 items carried no recommendation. Shareholder proposals: 5 FOR, 10 AGAINST, 5 abstained, by the filing’s own vote-source field.
The same two figures as Vanguard’s manager page (1,379,791 ballot items across 136 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Vanguard | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 98.0% | 796 | 94.5% | 1,082,514 |
| Backed environmental and social shareholder proposals at US companies | n/a | 6 | 0.9% | 6,718 |
Each ballot item this fund voted is set against the votes of the other Vanguard funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Vanguard funds on 12 items (2.1% of the 560 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Vanguard funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | 2026-05-05 | Shareholder Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director | For | AGAINST — 33 of 33 Vanguard funds | Against | Not approved, 27.6% support |
| Bristol-Myers Squibb Company | 2026-05-05 | Election of Directors: Derica W. Rice | Against | FOR — 34 of 34 Vanguard funds | Against | Elected, 97.2% support |
| Boston Scientific Corporation | 2026-04-30 | Proposal to elect ten Directors: David C. Habiger | Against | FOR — 27 of 27 Vanguard funds | Against | Elected, 85.9% support |
| Boston Scientific Corporation | 2026-04-30 | Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." | For | AGAINST — 27 of 28 Vanguard funds | Against | Not approved, 42.8% support |
| Incyte Corporation | 2026-06-08 | Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. Baker | Against | FOR — 25 of 26 Vanguard funds | Against | Elected, 80.9% support |
| Avantor, Inc. | 2026-05-07 | Election of Directors: Gregory Summe | Against | FOR — 16 of 16 Vanguard funds | Against | Passed (calculated), 87.0% support |
| Madrigal Pharmaceuticals, Inc. | 2026-06-17 | Re-election of Class I directors: Julian Baker | Withhold | FOR — 15 of 15 Vanguard funds | Against | Elected, 88.6% support |
| AbbVie Inc. | 2026-05-08 | Shareholder Stockholder proposal - to adopt a policy to require an independent chair | For | AGAINST — 29 of 31 Vanguard funds | Against | Not approved, 39.6% support |
| Mineralys Therapeutics, Inc. | 2026-05-21 | Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders: Srinivas Akkaraju, M.D., Ph.D. | For | WITHHOLD — 12 of 12 Vanguard funds | For | Passed (calculated), 60.6% support |
| Vertex Pharmaceuticals Incorporated | 2026-05-13 | Shareholder Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. | For | AGAINST — 21 of 23 Vanguard funds | Against | Approved, 57.0% support |
| Eli Lilly and Company | 2026-05-04 | Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. | For | AGAINST — 27 of 37 Vanguard funds | Against | Not approved, 33.7% support |
| Moderna, Inc. | 2026-05-06 | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Against | FOR — 17 of 30 Vanguard funds | Against | Approved, 65.1% support |
Download all 12 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 64.3% of this fund’s 900 such votes could be given a sector; the other 321 (35.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 517 | 14 | 2.7% |
| Industrials | 45 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 559 | 0 |
| Corporate Governance | 86 | 5 |
| Audit-related | 82 | 0 |
| Say-on-Pay | 66 | 0 |
| Capital Structure | 61 | 0 |
| Compensation | 58 | 0 |
| Shareholder Rights and Defenses | 12 | 4 |
| Other Social Issues | 7 | 4 |
| Extraordinary Transactions | 3 | 0 |
| Diversity, Equity, and Inclusion | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $10.4B | 10 | 2 |
| Merck & Co., Inc. | May 26, 2026 | $5.1B | 18 | 3 |
| Edwards Lifesciences Corporation | May 7, 2026 | $3.3B | 12 | 0 |
| UnitedHealth Group Incorporated | June 1, 2026 | $3.3B | 12 | 1 |
| Johnson & Johnson | April 23, 2026 | $3.0B | 15 | 1 |
| Danaher Corporation | May 5, 2026 | $2.2B | 14 | 0 |
| Abbott Laboratories | April 24, 2026 | $2.1B | 16 | 0 |
| Cencora, Inc. | March 5, 2026 | $2.0B | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder proposal - to adopt a policy to require an independent chair Shareholder proposal | For | Against |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| May 13, 2026 | Elevance Health, Inc. | Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposal | Against | For |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposal | Against | For |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding shareholders' right to act by written consent. Shareholder proposal | Against | For |
936 ballot items at 91 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Vanguard Health Care Fund (VGHAX) voted at 91 shareholder meetings of 81 companies, on 936 ballot items in all. Where management made a recommendation, the fund followed it on 97.7% of the items and voted against it 15 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 20 shareholder proposals. It voted FOR the board's own proposals more often than Vanguard's funds as a whole (98.0% against 94.5%). It voted differently from most Vanguard funds on 12 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Vanguard’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.